vTv Therapeutics
VTVT
44 hedge funds and large institutions have $22.1M invested in vTv Therapeutics in 2017 Q4 according to their latest regulatory filings, with 9 funds opening new positions, 13 increasing their positions, 12 reducing their positions, and 2 closing their positions.
350% more first-time investments, than exits
New positions opened: 9 | Existing positions closed: 2
19% more funds holding
Funds holding: 37 → 44 (+7)
8% more capital invested
Capital invested by funds: $20.4M → $22.1M (+$1.66M)
8% more repeat investments, than reductions
Existing positions increased: 13 | Existing positions reduced: 12
0.07% more ownership
Funds ownership: 0.88% → 0.95% (+0.07%)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
RA
Royce & Associates
New York
|
+$1.26M |
| 2 |
JP Morgan Chase
New York
|
+$715K |
| 3 |
Millennium Management
New York
|
+$351K |
| 4 |
Creative Planning
Overland Park,
Kansas
|
+$106K |
| 5 |
State Street
Boston,
Massachusetts
|
+$70.2K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BlackRock
New York
|
-$391K |
| 2 |
CS
Candriam SCA
Strassen, Luxembourg,
Luxembourg
|
-$280K |
| 3 |
Franklin Resources
San Mateo,
California
|
-$275K |
| 4 |
Alyeska Investment Group
Chicago,
Illinois
|
-$107K |
| 5 |
SFM
Sphera Funds Management
Tel Aviv,
Israel
|
-$103K |
VTVT Hedge Fund Activity: Q4 2017 in Review
44 of the 4,409 institutional investors tracked by Wall St. Rank reported a position in vTv Therapeutics (VTVT) for Q4 2017, worth a combined $22.1M — up 8.1% from $20.4M a quarter earlier.
Buyers outnumbered sellers: 9 funds opened new VTVT positions and 2 closed out — a net gain of 7 holders — while 13 added to existing stakes and 12 trimmed.
The largest buyer was Royce & Associates, opening a new position worth an estimated $1.26M. The largest seller was BlackRock, cutting an estimated $391K.
- 44 institutional investors held vTv Therapeutics (VTVT) as of Q4 2017, up from 37 in Q3 2017.
- Funds reported $22.1M of vTv Therapeutics stock for Q4 2017, up 8.1% quarter-over-quarter.
- 9 funds opened new vTv Therapeutics positions in Q4 2017 and 2 closed out, a net change of +7 holders.
- The largest vTv Therapeutics buyer in Q4 2017 was Royce & Associates, an estimated $1.26M added.
- The largest vTv Therapeutics seller in Q4 2017 was BlackRock, an estimated $391K sold.
Based on aggregated 13F filings for Q4 2017.